Biontech Se ADR BNTX

$BNTX has inferior technology. mRNA was a moon shot; only $MRNA was successful. BioNTech is on a plane at full speed into the ground. Yes, there is hope in the future - but how long do you need to wait. The risk is that Moderna mRNA expertise increasingly pulls away from BNTX. Will continue to watch and when they have first breakthrough jump in or maybe reboard sometime next year if the cash burn is not too bad. A massive residual risk is the mRNA technology role - still unfilled? REALLY? Guido Oelkers looks like a great leader but has zero mRNA experience, not a mRNA scientific pioneer. Yikes. At this moment, BNTX is a no touch. Was fortunate and lucky to exit a bit before the CEO and CMO announced their departure. Do not expect anything good in the near term.

$IBRX $XBI one more time! Good morning World! Xbi looking good as are all bios like $MRNA $MRK sucks for bcg shortage Scott Gottlieb was on msn fast money pushing pfe vax but their partner $BNTX had major setback on that front🤷‍♂️ Ibrx has that bull flag w breakout once cross over 9.85 again past 10.65 into 12+++

BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles $BNTX $FBT $IBB https://stocktwits.com/news/equity/markets/bntx-stock-selloff-deepens-doubts-bmo-ties-bnt-113-miss-to-wider-m-rna-cancer-vaccine-struggles/cZxBx6kRBYA

$BNTX German mRNA drugmaker BioNTech's BNT113 missed its first primary endpoint in head and neck cancer: adding it to pembrolizumab gave no significant progression-free survival gain. BioNTech had €16.6 billion in cash, cash equivalents and security investments, Q2 2026 revenues of €105.6 million and full-year 2026 revenue guidance of €1.6–1.9 billion; BNT113 was one of its expected 2026 late-stage readouts. Shares closed $95.82 Oct 12, 2026. Other side: trial runs on; a significant overall-survival result would still make it positive, no date given.

$BNTX not adding today. Got enough shares to be content if I miss this "dip".

$BNTX Going to 80's. Leaderless until February. Their technology did not work and the best ideas are walking out the door with the CEO's and CMO's departure. Just a company wondering in the desert and all their supplies taken.

$NVAX $BNTX BNT113 missed PFS today in Ahead-Merit – fixed-antigen mRNA plus Keytruda didn't beat Keytruda alone in HPV16+ head and neck. OS endpoint continues, so not dead. $BNTX –5%, $MRNA –3%, $NVAX traded green. What today does NOT show: that protein beats mRNA. Merck and Moderna's personalised mRNA vaccine hit Phase 3 in August on the same LNP platform. The variable was antigen selection, not delivery. Anyone claiming otherwise will get that thrown back at them. What is true, independent of today, is why the adjuvanted protein route is a serious parallel path in oncology: Mechanism – saponins drive cholesterol-dependent endosomal escape, which puts antigen into the MHC-I pathway and generates the CD8 cytotoxic T cells that actually kill tumour cells. Precedent – QS-21, the same raw material as Matrix-M, is in GSK's AS01. Shingrix produces the most durable T-cell responses of any licensed adjuvant. Tolerability – therapeutic cancer vaccines are given repeatedly to patients already carrying chemo and checkpoint toxicity. BEEHIVE, randomised head-to-head: 62% vs 76% systemic reactions, grade 2+ 16% vs 34%. That gap matters far more in oncology than in routine immunisation. Logistics – 2–8°C, no ultracold chain, for a product administered over months in community oncology. IP – no LNP, no modified nucleosides, none of the litigation Moderna, BioNTech, Pfizer, Alnylam, Arbutus and now Bayer are fighting over. Novavax has no therapeutic cancer vaccine in the clinic – nine Novavax authors on an AACR immuno-oncology abstract is preclinical, and I'll say so. The real read on the field comes Oct 24 at ESMO. NFA. Long $NVAX.